Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Heather Hunter's research focuses on diabetes management, particularly the use of automated insulin delivery systems in adults with both Type 1 and Type 2 diabetes. Her work investigates the benefits of these systems across different patient populations, including those with varying C-peptide levels and in conjunction with other treatments like GLP-1 receptor agonists. Hunter also examines the impact of automated insulin delivery in individuals with Type 2 diabetes who have GAD65 antibodies. Additionally, her research extends to the social determinants of health, exploring the association of perceived discrimination with functional limitations among immigrant women and perceptions of discrimination among middle-aged and older Black Americans. She has also studied predictors of liver function among Mexican Americans with disabling arthritis.
Metrics
- h-index: 5
- Publications: 12
- Citations: 80
Selected Publications
-
The Association of Perceived Discrimination to Functional Limitation Among Immigrant Women Living in the U.S. (2025)
-
MIDDLE AGED AND OLDER BLACK AMERICAN PERCEPTIONS OF DISCRIMINATION (2024)
-
PREDICTORS OF LIVER FUNCTION AMONG MEXICAN AMERICAN WITH DISABLING ARTHRITIS (2024)
Collaboration Network
Top Collaborators
- Real-World, Patient-Reported and Clinic Data from Individuals with Type 1 Diabetes Using the MiniMed 670G Hybrid Closed-Loop System
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
Showing 5 of 6 shared publications
- Real-World, Patient-Reported and Clinic Data from Individuals with Type 1 Diabetes Using the MiniMed 670G Hybrid Closed-Loop System
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
Similar Researchers
Based on overlapping research topics